It will become routine in ten years to look at the plaintiff’s genome on a chip. And the attorneys on both sides should be cross-examining that information.
— Professor Gary Marchant at Arizona State University Sandra Day O’Connor College of Law.
Marchant’s comments came in a story from Bloomberg BNA’s Peter Hayes , who explored the notion of litigators using a plaintiff’s genome as evidence in defending toxic tort cases against their corporate clients.
Per the article:
Traditional causation in toxic tort cases involves epidemiological evidence, which attempts to establish whether there is a correlation between a risk factor and ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.